Park In Ja, Kim Hee Cheol, Yu Chang Sik, Kim Tae Won, Jang Se Jin, Kim Jin Cheon
Department of Surgery, University of Ulsan College of Medicine, Asan Medical Center, and Asan Cancer Center, Seoul 138-736, Korea.
Ann Surg Oncol. 2008 Feb;15(2):519-25. doi: 10.1245/s10434-007-9643-x. Epub 2007 Oct 25.
Prospective trials have demonstrated that chemotherapy combined with radiotherapy decreases local recurrence rates in stage II and stage III rectal cancer. Some patients with stage II lesions, however, have relatively low risks of local recurrence. We evaluated the effect of radiotherapy on local recurrence in patients with stage IIA rectal cancer.
From the colorectal cancer database, we identified 390 stage IIA rectal cancer patients who underwent curative resection followed by adjuvant therapy from 1995 to 2002; a total of 72 patients who received preoperative chemoradiotherapy and who did not receive adjuvant therapy were excluded. Mean follow-up period was 65 months (range, 2-133 months).
Of the 390 patients, 110 had primary tumors in the upper rectum, 136 in the midrectum, and 144 in the lower rectum. Lymphovascular invasion was observed in 35 patients (9.0%). Mean (+/- SD) number of examined lymph nodes was 18 (+/- 12). Adjuvant chemotherapy was provided to 180 patients (46.2%), and chemotherapy plus radiotherapy was provided to 210 patients (53.8%). Radiotherapy was significantly more common in younger patients (P = .01) and those with lower rectal cancer (P < .001). Local recurrence rate did not differ between patients who did and did not receive radiotherapy. In patients with mid and lower rectal cancer, the local recurrence rate was not affected by radiotherapy.
Radiotherapy did not seem to provide additional benefit in decreasing local recurrence rate of stage IIA rectal cancers. In selected patients, however, the role of radiotherapy needs to be carefully evaluated.
前瞻性试验表明,化疗联合放疗可降低II期和III期直肠癌的局部复发率。然而,一些II期病变患者的局部复发风险相对较低。我们评估了放疗对IIA期直肠癌患者局部复发的影响。
从结直肠癌数据库中,我们确定了1995年至2002年期间接受根治性切除并辅助治疗的390例IIA期直肠癌患者;总共72例接受术前放化疗且未接受辅助治疗的患者被排除。平均随访期为65个月(范围2 - 133个月)。
在这390例患者中,110例原发肿瘤位于直肠上段,136例位于直肠中段,144例位于直肠下段。35例患者(9.0%)观察到淋巴管浸润。检查的淋巴结平均数量为18个(±12个)。180例患者(46.2%)接受辅助化疗,210例患者(53.8%)接受化疗加放疗。放疗在年轻患者(P = 0.01)和直肠下段癌患者中(P < 0.001)更为常见。接受放疗和未接受放疗的患者局部复发率无差异。在直肠中段和下段癌患者中,局部复发率不受放疗影响。
放疗似乎并未在降低IIA期直肠癌局部复发率方面提供额外益处。然而,在特定患者中,放疗的作用需要仔细评估。